Clinical Study

Uccc-Hn-19-03- An Open-Label, Phase II Study Evaluating The Efficacy Of Niraparib And Dostarlimab (Tsr-042) In Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma Patients

Posted Date: Nov 24, 2020

  • Investigator: Trisha Wise-Draper
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to determine the best overall response of the combination of dostarlimab and niraparib in patients with recurrent and/or metastatic HNSCC patients. Patients will be treated with combination of the PD-1 inhibitor (dostarlimab) and PARPi (niraparib) concurrently.The primary outcomes measured are Overall response rate, progression free survival, and overall survival.

Criteria:

To Be Eligible: Must Have Histologically, Cytologically, Or Radiographically Confirmed Recurrent Or Metastatic Non Cutaneous Hnscc For Which There Are No Surgical Or Radiation Curative Options, Ecog 0-2, No Nasopharyngeal And Salivary Gland Tumors, No Hypersensitivity To Study Drugs Or Excipients, No Uncontrolled Intercurrent Illness, No Prior Exposure To Both Immunotherapy Drugs

Keywords:

Hnscc, Head And Neck Cancer

For More Information:

Uc Cancer Center
513-584-7658
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.